Matuguina, Mark John .
HRN: 24-79-98 Sex: MalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/11/2024
CO-AMOXICLAV 457MG/5ML, 70ML SUSPENSION (BOT)
04/11/2024
04/18/2024
PO
6ml
Q8h
Laceration
Waiting Final Action
Indication: Empiric Type of Infection: Urinary TractSkin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes